Randall Michael Giuffre - 02 Jan 2026 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role: Director
Signature: /s/ Scott Kellen, attorney-in-fact
Issuer symbol: DMAC
Transactions as of: 02 Jan 2026
Net transactions value: +$51,994
Form type: 4
Filing time: 06 Jan 2026, 17:24:08 UTC
Previous filing: 03 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Giuffre Randall Michael	Director	301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS	/s/ Scott Kellen, attorney-in-fact	06 Jan 2026	0001759822

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DMAC	Common Stock	Award	$51,994	+6,175	+1.6%	$8.42	398,587	02 Jan 2026	Direct	F1
holding	DMAC	Common Stock						25,573	02 Jan 2026	See footnote	F2
holding	DMAC	Common Stock						21,070	02 Jan 2026	By Spouse

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees in the aggregate amount of $52,000. The deferred stock units are scheduled to vest in four nearly equal installments on each of March 31, June 30, September 30, and December 31, 2026.
F2	These voting common shares are held by 424822 Albert Ltd, of which Michael Giuffre has sole voting and dispositive power.